搜索筛选:
搜索耗时2.1290秒,为你在为你在102,285,761篇论文里面共找到 11 篇相符的论文内容
发布年度:
[会议论文] 作者：Ziwen Zhang,Tingting Zhang,Yuxian Bai,
来源：第十二届国际胃癌学术会议 年份：2017
...
[会议论文] 作者：shumin li,Yanjing Li,Yuxian Bai,
来源：2019中国肿瘤学大会 年份：2019
Objective Esophageal cancer is the eighth most common cancer worldwide,and the sixth leading cause of cancer-related mortality....
Arsenic trioxide enhances the therapeutic efficacy of adjuvant post-operative chemotherapy of gastri
[期刊论文] 作者：Hong Sui,Yuxian Bai,Yu Han,Kai,
来源：中德临床肿瘤学杂志：英文版 年份：2009
如果，学习的目的是调查未来的学习的目的有砷三氧化物的治疗(作为 2 O 3) 能为胃的癌症病人作为辅助手术后的化疗提高没有疾病的幸存并且保护骨头髓免...
[会议论文] 作者：Rui Xie,Yanjing Li,Hong Sui,Xiaoli Wei,Yuxian Bai,
来源：第十届全国胃癌学术会议暨第三届阳光长城肿瘤学术会议 年份：2015
...
808 nm near infrared light excited UCNPs@mSiO2-Ce6-GPC3 nanocomposites for photodynamic therapy in l
[会议论文] 作者：Rui Xie,Jiahe Hu,Yufeng Wang,Wei Yang,Ping Liu,Qinghao Liu,Yuxian Bai,Jiuxin Zhu,
来源：2019中国肿瘤学大会 年份：2019
Objective Liver cancer is an invasive tumor originating from the liver,it causes great harm to human health.Its global incidence rate is the fifth among men and the seventh among women....
The result of Phase 1b and phase 2 study of selective VEGFR inhibitor fruquintinib as 3+ line therap
[会议论文] 作者：Jin Li,Ruihua Xu,Junning Cao,Yuxian Bai,Jianming Xu,Tianshu Liu,Lin Shen,Liwei Wang,Hongming Pan,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: Fruquintinib is a novel oral small molecule compound selectively inhibits vascular endothelial growth factor receptors (VEGFR)1, 2, and 3 with potent inhibitory effects on multiple human tu...
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced eso
[期刊论文] 作者：Ming Bai,Meng Wang,Ting Deng,Yuxian Bai,Kai Zang,Zhanhui Miao,Wenlin Gai,Liangzhi Xie,Yi Ba,
来源：癌症生物学与医学（英文版） 年份：2022
Objective: The mainstay treatment of esophageal squamous cell carcinoma (ESCC) involves chemotherapy and immunotherapy. However, alternative therapies are required for patients who are refractory or intolerant to existing therapies. Methods......
The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or me
[期刊论文] 作者：Fang,Ping Lu,Qingxia Fan,Yongqian Shu,Jifeng Feng,Shu Zhang,Yi Ba,Yang Zhao,Ying Liu,Chunmei Bai,Yuxian Bai,
来源：癌症生物学与医学（英文版） 年份：2021
Objective:In this post-hoc analysis, we evaluated anlotinib treatment-induced hypertension as a potential predictive factor of efficacy in esophageal squamous c...
A randomized,double-blind,multicenter,Phase2,three-arm,placebo-control study of apatinib as third li
[会议论文] 作者：Cheng,Zhehai Wang,Leizhen Zheng,Min Tao,xiaodong Zhu,Dongmei Ji,Xin Liu,weijian Guo,Jianping Xiong,Yuxian Bai,
来源：第十五届全国临床肿瘤学大会暨2012年CSCO学术年会 年份：2012
...
A randomized,double-blind,multicenter,Phase2,three-arm,placebo-control study of apatinib as third li
[会议论文] 作者：Zheng,Min Tao,xiaodong Zhu,Dongmei Ji,Xin Liu,Shukui Qin,Jianming Xu,weijian Guo,Jianping Xiong,Yuxian Bai,
来源：第十五届全国临床肿瘤学大会暨2012年CSCO学术年会 年份：2012
...
Efficacy and safety of regorafenib (REG) monotherapy in Chinese patients with previously treated met
[会议论文] 作者：Ruihua Xu,Jin Li,Thomas CC Yau,Brigette Ma,Hongming Pan,Jianming Xu,Yuxian Bai,Yihebali Chi,Liwei Wang,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: The new oral multi-kinase inhibitor REG improves overall survival (OS) in mCRC patients who progress after standard therapies.CONCUR (NCT01584830) evaluated the efficacy and safety of REG i...
相关搜索：
